Search results for "double-blind"

showing 10 items of 662 documents

Safety and efficacy of an intra-oral electrostimulator for the relief of dry mouth in patients with chronic graft versus host disease: case Series

2013

Objectives: Patients with chronic graft-versus-host disease (cGVHD) often suffer from dry mouth and oral mucosal lesions. The primary objective of this study was to investigate the safety of an intra-oral electrostimulator (GenNarino) in symptomatic cGVHD patients. The secondary objective was to study the impact on the salivary gland involvement of cGVHD patients. Study Design: This paper presents a case series. The study included patients treated for 4 weeks, randomly assigned to the active device and then crossed-over to a sham-device or vice versa. The patients and clinicians were blind to the treatment delivered. Data regarding oral mucosal and salivary gland involvement were collected.…

AdultMalemedicine.medical_specialtyGraft vs Host DiseaseElectric Stimulation TherapyOdontologíaDiseaseXerostomiaSalivary Glandslaw.inventionDouble-Blind MethodRandomized controlled triallawInternal medicinehemic and lymphatic diseasesmedicineHumansIn patientGeneral DentistryAgedOral Medicine and PathologySalivary glandbusiness.industryResearchMucosal lesionsEquipment DesignMiddle Agedmedicine.diseaseDry mouth:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryTreatment Outcomemedicine.anatomical_structureGraft-versus-host diseaseOtorhinolaryngologyIntra oralUNESCO::CIENCIAS MÉDICASFemaleSurgerymedicine.symptombusiness
researchProduct

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

2013

Globotriaosylceramide concentrations were assessed as potential predictors of change from baseline after 12 months by estimated glomerular filtration rate and left-ventricular mass index using pooled data from three randomized, placebo-controlled agalsidase alfa trials and open-label extensions of patients with Fabry disease.Males (aged 18 years or older) with Fabry disease received agalsidase alfa (0.2 mg/kg every other week for 12 months). A backward-elimination approach evaluated potential predictors (baseline estimated glomerular filtration rate and left-ventricular mass index; age at first dose; baseline and change from baseline at 12 months of globotriaosylceramide (urine, plasma); ur…

AdultMalemedicine.medical_specialtyHeart VentriclesUrologyGlobotriaosylceramideRenal functionUrinechemistry.chemical_compoundYoung Adultstomatognathic systemDouble-Blind MethodMedicineHumansRenal Insufficiency Chronicskin and connective tissue diseasesGenetics (clinical)Alpha-galactosidasebiologybusiness.industryTrihexosylceramidesvirus diseasesEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseasedigestive system diseasesRecombinant ProteinsIsoenzymesTreatment Outcomechemistryalpha-Galactosidasebiology.proteinDisease ProgressionBiomarker (medicine)Fabry Diseasesense organsbusinessBiomarkersKidney diseaseGlomerular Filtration RateGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

Immunological study of Melkersson-Rosenthal syndrome. Lack of response to food additive challenge

1995

Summary A study was made of six patients with Melkersson-Rosenthal syndrome (MRS) to establish the aetiological role of foodstuffs and/or additives and the possible associated immunological alterations. In all cases Melkersson-Rosenthal syndrome (MRS) was diagnosed both clinically and histologically, excluding other causes of orofacial granulomatosis (OFG). A detailed study of possible triggering factors was performed in all patients. Blood analysis, x-rays and cultures, were always within normal limits, with the exception of the finding of circulating immune complexes (CICs) in three patients with facial palsy associated, and C-reactive protein positivity in two patients who presented pers…

AdultMalemedicine.medical_specialtyImmunologyProvocation testAntigen-Antibody ComplexAsymptomaticAtopyDouble-Blind MethodMelkersson–Rosenthal syndromemedicineHumansImmunology and AllergySensitizationSkin TestsMelkersson-Rosenthal Syndromebusiness.industryMiddle Agedmedicine.diseaseDermatologyFacial paralysisC-Reactive Proteinmedicine.anatomical_structureFoodImmunologyEtiologyFemaleFood AdditivesOrofacial granulomatosismedicine.symptombusinessFood HypersensitivityClinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy
researchProduct

Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial.

2011

Objective To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia. The device delivers electrostimulation through the oral mucosa to the lingual nerve in order to enhance the salivary reflex. Methods The device was tested on a sample of patients with xerostomia due to Sjogren's syndrome and other sicca conditions in a 2-stage prospective, randomized, multicenter trial. Stage I was a double-blind, crossover stage designed to compare the effects of the electrically active device with the sham device, each used for 1 month, and stage II was a 3-month open-label stage d…

AdultMalemedicine.medical_specialtyImmunologySettore MED/50 - Scienze Tecniche Mediche ApplicateElectric Stimulation TherapySeverity of Illness IndexXerostomialaw.inventionRandomized controlled trialQuality of lifestomatognathic systemRheumatologyDouble-Blind MethodlawSettore MED/28 - Malattie OdontostomatologicheMulticenter trialSeverity of illnessotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansPharmacology (medical)Prospective StudiesOral mucosaProspective cohort studyAgedxerostomia; dry mouth; salivary gland hypofunction; saliva; electrical stimulation; electrostimulation; Sjögren’s syndromeIntention-to-treat analysisToxicitybusiness.industryMouth MucosaMiddle AgedDry mouthSurgeryOral cavityIntention to Treat Analysisstomatognathic diseasesmedicine.anatomical_structureSjogren's SyndromeTreatment OutcomeAnesthesiaFemalemedicine.symptombusinessArthritis and rheumatism
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Effect of dual blockade of renin–angiotensin system on TGFβ1 and left ventricular structure and function in hypertensive patients

2007

The effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on left ventricular mass (LVM), circulating transforming growth factor beta1 (TGFbeta1), procollagen type I (PIP) and III (PIIIP), have been evaluated in hypertensive (HT) patients. A total of 57 HT with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, three arms, double dummy, independent trial was used. All HT patients were randomly allocated to three treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/ daily) and combined (losartan 50 mg/daily + ramipril 5 mg/daily) for 24 weeks. TGFbeta1, PIP and PIIIP, LVM, LVM/h(2.7) and other echo…

AdultMalemedicine.medical_specialtyLeft ventricular structureHeart VentriclesBlood PressureEnzyme-Linked Immunosorbent AssayAngiotensin II Receptor BlockersPeptide hormoneSeverity of Illness IndexDual blockadeCollagen Type ILosartanVentricular Function LeftRenin-Angiotensin SystemTransforming Growth Factor beta1Double-Blind MethodRamiprilInternal medicineRenin–angiotensin systemPrevalenceInternal MedicineHumansMedicineAntihypertensive AgentsUltrasonographyAnalysis of Variancebusiness.industryMiddle AgedAngiotensin IICollagen Type IIITreatment OutcomeEndocrinologyItalyHypertensionACE inhibitorDrug Therapy CombinationFemaleHypertrophy Left VentricularbusinessBiomarkersmedicine.drugJournal of Human Hypertension
researchProduct

Influence of loperamide and loperamide oxide on the anal sphincter

1992

The objective of this study was to investigate the effects of the opioid loperamide and its recently synthesized pharmacologically inactive prodrug loperamide oxide on the anal sphincter. In a double-blind, placebo-controlled crossover study, anorectal manometry was performed in 12 healthy volunteers five hours after oral bolus application of 10 mg of loperamide, loperamide oxide, or placebo. Loperamide significantly increased the threshold volumes for minimal perception and urgency to defecate (P less than 0.05) and raised the volume required to abolish recovery of the rectoanal inhibitory reflex (P less than 0.05). These findings suggest that loperamide has a specific continence-improving…

AdultMalemedicine.medical_specialtyLoperamideManometryAnal CanalPlaceboLoperamideGastroenterologyBolus (medicine)Double-Blind MethodInternal medicinePressuremedicineHumansDefecationbusiness.industryAnorectal manometryRectumGastroenterologyGeneral MedicineProdrugCrossover studyOpioidDefecationFemalebusinessmedicine.drugDiseases of the Colon & Rectum
researchProduct

Botulinum toxin vs. topical glyceryl trinitrate ointment for pain control in patients undergoing hemorrhoidectomy: a randomized trial.

2007

PURPOSE: The maximum resting pressure in the anal canal is greatly raised after hemorrhoidectomy. This increase is likely to be the cause of postoperative pain, which is still the most troublesome early problem after hemorrhoidectomy. This study was designed to compare, after hemorrhoidectomy, the effects of intrasphincter injection of botulinum toxin vs. application of glyceryl trinitrate ointment in improving wound heating and reducing postoperative pain at rest or during defecation. METHODS: Thirty patients with hemorrhoids of third and fourth degree were included in the study and randomized in two groups. Anorectal manometry was performed preoperatively and 5 and 40 days after hemorrhoi…

AdultMalemedicine.medical_specialtyManometryRestMULTICENTERPLACEBO-CONTROLLED TRIALHemorrhoidslaw.inventionInjectionsOintmentsNITROGLYCERIN OINTMENTNitroglyceringlyceryl trinitrateHemorrhoidsHEADACHERandomized controlled triallawmedicineHumansbotulinum toxinBotulinum Toxins Type AAdverse effectDefecationNEURONSPain MeasurementPain PostoperativeNITRIC-OXIDEhemorrhoidectomy CHRONIC ANAL-FISSUREbusiness.industryAnorectal manometryGastroenterologyGeneral MedicineAnal canalmedicine.diseaseDOUBLE-BLIND TRIALBotulinum toxinColorectal surgerySurgerymedicine.anatomical_structureTreatment OutcomeSPHINCTEROTOMYNeuromuscular AgentsAnesthesiaDefecationFemalebusinessmedicine.drugDiseases of the colon and rectum
researchProduct

Double-blind cross-over study with oral alpha-ketoacids in patients with chronic renal failure.

1980

In 15 ambulatory patients with renal insufficiency (creatinine clearance, 9.9 +/- 3.0 ml/min) the effect of oral supplementation with alpha-ketoacids has been compared with that of placebo. The protein intake amounted to 0.55 g protein per kilogram body weight of high biological value, as estimated by dietary recordings. After a control period of 3 months the patients received, in a double-blind study, 1.05 g alpha-ketoacids/10 kg body weight per day or a placebo for 6 weeks with a subsequent cross-over. Fasting blood samples were analyzed at 3-week intervals for routine laboratory parameters and 17 proteins. Anthropometric and clinical data have been recorded every 3 weeks. While therapy w…

AdultMalemedicine.medical_specialtyMedicine (miscellaneous)Renal functionAlpha (ethology)PlaceboGastroenterologyPhosphatesPlacebosElectrolytesDouble-Blind MethodInternal medicinemedicineHumansClinical Trials as TopicNutrition and Dieteticsbusiness.industrynutritional and metabolic diseasesBiological valueBlood ProteinsAnthropometryMiddle AgedCrossover studyKeto AcidsDietClinical trialEndocrinologyCreatinineAmbulatoryKidney Failure ChronicFemalebusinessThe American journal of clinical nutrition
researchProduct